Sustainability | September 12, 2023
JB Pharma publishes sustainability report for FY 2022-23
JB Pharma reported 19% decrease in GHG intensity as compared to last year and commenced its journey of Scope 3 emissions
JB Pharma reported 19% decrease in GHG intensity as compared to last year and commenced its journey of Scope 3 emissions
Teva will leverage Honeywell’s ‘Energy as a Service’ (EaaS) model
Good momentum in commercial CDMO business
New reforestation projects in Brazil, India, Vietnam, Ghana and Rwanda in addition to existing projects including in Australia and Indonesia
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
The new Biolys provides higher concentration of L-lysine
The target boundary includes biogenic land?related emissions and removals from bioenergy feedstock
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
_256_384.png)
Amongst the first pharmaceutical companies in India and Asia to be recognised for adopting advanced fourth industrial revolution technologies to digitally transform operations
Subscribe To Our Newsletter & Stay Updated
